Axelopran/oxycodone - Theravance Biopharma
Alternative Names: Oxycodone/alexopran; Oxycodone/TD-1211; TD-1211/oxycodoneLatest Information Update: 01 Oct 2021
At a glance
- Originator Theravance Biopharma
- Class Aza compounds; Benzamides; Cyclohexanes; Heterocyclic bicyclo compounds; Laxatives; Morphine derivatives; Opioid analgesics; Small molecules; Tropanes
- Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Constipation; Pain
Most Recent Events
- 01 Oct 2021 Discontinued - Phase-II for Constipation in Australia (PO) (Theravance Biopharma pipeline, October 2021)
- 01 Oct 2021 Discontinued - Phase-II for Pain in Australia (PO) (Theravance Biopharma pipeline, October 2021)
- 19 Mar 2019 Axelopran/oxycodone is still in phase II trials for Pain and opioid induced Constipation in Australia (Theravance Biopharma website, March 2019)